How common is Prostate cancer?

Lalela leli khasi

Kuvame kangakanani umdlavuza we-prostate?

Umdlavuza we-prostate ungenye yezinhlobo ezivame kakhulu zomdlavuza emadodeni, ikakhulukazi emadodeni amadala.

Ngokwe-American Cancer Society, umdlavuza we-prostate uwumdlavuza wesibili ovame kakhulu emadodeni aseMelika, ngemva komdlavuza wesikhumba.

E-United States, cishe owesilisa oyedwa kwabayisishiyagalolunye uzothola ukuthi unesifo somdlavuza we-prostate phakathi nokuphila kwakhe.

Kulinganiselwa ukuthi ngo-2021, kuzoba namacala amasha omdlavuza we-prostate angaba ngu-248,530 nokufa okungaba ngu-34,130 ngenxa yomdlavuza we-prostate.

Nokho, kubalulekile ukuphawula ukuthi umdlavuza we-prostate uyelashwa kalula, futhi izinga lokusinda liphakeme lapho kutholakala kusenesikhathi.

Izikhombo

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Fesinmeyer MD, Gulati R, Zeliadt S, Weiss N, Kristal AR, Etzioni R: Effect of population trends in body mass index on prostate cancer incidence and mortality in the United States. Cancer Epidemiol Biomarkers Prev. 2009, 18 (3): 808-15.

Peng P, Gong YM, Bao PP, Ke JZ, Xiang YM, Zhang ML, Zheng Y: [Estimates and prediction of prostate cancer incidence, mortality and prevalence in China, 2008]. Zhonghua Liu Xing Bing Xue Za Zhi. 2012, 33 (10): 1056-9.

Delongchamps NB, Singh A, Haas GP: The role of prevalence in the diagnosis of prostate cancer. Cancer Control. 2006, 13 (3): 158-68.

Li J, German R, King J, Joseph D, Thompson T, Wu XC, Ajani U, Tai E: Recent trends in prostate cancer testing and incidence among men under age of 50. Cancer Epidemiol. 2012, 36 (2): 122-7.

Yu XQ, Luo Q, Smith DP, Clements MS, O'Connell DL: Prostate cancer prevalence in New South Wales Australia: a population-based study. Cancer Epidemiol. 2015, 39 (1): 29-36.

Ondrusova M, Mrozova L, Ondrus D, Mrinakova B: Trends and estimates in prostate cancer incidence, mortality and prevalence in the Slovak Republic, 1968-2012. Neoplasma. 2013, 60 (4): 446-51.

Ukuzikhulula: kwezokwelapha

Le webhusayithi inikezwa ngezinjongo zemfundo nezokwaziswa kuphela futhi ayifaki ukunikeza izeluleko zezokwelapha noma izinsizakalo zobungcweti.

Imininingwane enikeziwe akufanele isetshenziselwe ukuxilonga noma ukwelapha inkinga noma isifo, futhi labo abafuna iseluleko somuntu siqu sezokwelapha kufanele babonane nodokotela onelayisense.

Sicela uqaphele ukuthi inethiwekhi ye-neural ekhiqiza izimpendulo zemibuzo, ayinembile ngokukhethekile uma kuziwa kokuqukethwe kwezinombolo. Ngokwesibonelo, inani labantu abanesifo esithile.

Ngaso sonke isikhathi funa iseluleko sikadokotela wakho noma omunye umhlinzeki wezempilo ofanelekayo mayelana nesimo sezokwelapha. Ungalokothi ungayinaki iseluleko sezokwelapha sobungcweti noma ubambezele ukusifuna ngenxa yento oyifundile kule webhusayithi. Uma ucabanga ukuthi ungase ube nesimo esiphuthumayo sezokwelapha, shayela i-911 noma uye egumbini lezimo eziphuthumayo eliseduze ngokushesha. Ayikho ubudlelwano bokuthi udokotela-isiguli obakhiwe yile webhusayithi noma ukusetshenziswa kwayo. I-BioMedLib noma abasebenzi bayo, noma noma yimuphi umnikeli wale webhusayithi, akenzi noma yimiphi imibono, ecacile noma ecacile, mayelana nolwazi olunikezwe lapha noma ukusetshenziswa kwayo.

Ukuzikhulula: amalungelo obunikazi

I-Digital Millennium Copyright Act ka-1998, i-17 U.S.C. § 512 (i- DMCA) inikeza indlela yokuphendula kubanikazi bamalungelo obunikazi abakholelwa ukuthi okokusebenza okubonakala kwi-Internet kwephula amalungelo abo ngaphansi komthetho we-copyright wase-US.

Uma ukholelwa ngobuqotho ukuthi noma yikuphi okuqukethwe noma okokusebenza okwenziwe kutholakale maqondana newebhusayithi yethu noma izinsizakalo kwephula ilungelo lakho lobunikazi, wena (noma umenzeli wakho) ungasithumela isaziso esicela ukuthi okuqukethwe noma okokusebenza kususwe, noma ukufinyelela kukho kuvinjelwe.

Izaziso kufanele zithunyelwe ngokubhala nge-imeyili (bheka isigaba esithi "Contact" ukuze uthole ikheli le-imeyili).

I-DMCA idinga ukuthi isaziso sakho sokwephulwa kwamalungelo obunikazi kubandakanye imininingwane elandelayo: (1) incazelo yomsebenzi onamalungelo obunikazi oyisihloko sokwephulwa okusolwa; (2) incazelo yokuqukethwe okusolwa ukwephula amalungelo obunikazi nolwazi olwanele ukusivumela ukuthi sithole okuqukethwe; (3) imininingwane yokuxhumana nawe, kufaka phakathi ikheli lakho, inombolo yocingo nekheli le-imeyili; (4) isitatimende sakho sokuthi unokholo oluhle lokuthi okuqukethwe ngendlela ekhonjiwe ngayo akugunyaziwe ngumnikazi wamalungelo obunikazi, noma umenzeli wakhe, noma ngokusebenza kwanoma imuphi umthetho;

(5) isitatimende sakho, esisayinwe ngaphansi kwesijeziso sokufakaza amanga, sokuthi ukwaziswa okusesazisweni kunembile nokuthi unegunya lokuphoqelela amalungelo obunikazi okuthiwa aphuliwe;

futhi (6) isignesha ebonakalayo noma ye-elekthronikhi yomnikazi we-copyright noma umuntu ogunyaziwe ukuba asebenze egameni lomnikazi we-copyright.

Ukwehluleka ukufaka yonke imininingwane engenhla kungaholela ekubambezelweni kokucutshungulwa kwesikhalazo sakho.

Othintana naye

Sicela usithumelele i-imeyili nganoma yimiphi imibuzo / iziphakamiso.

How common is prostate cancer?

Prostate cancer is one of the most common types of cancer in men, particularly in older men.

According to the American Cancer Society, prostate cancer is the second most common cancer in American men, behind skin cancer.

In the United States, about 1 in 9 men will be diagnosed with prostate cancer during their lifetime.

In 2021, it is estimated that there will be about 248,530 new cases of prostate cancer and about 34,130 deaths from prostate cancer.

However, it is important to note that prostate cancer is highly treatable, and the survival rate is high when it is detected early.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.